Search

Your search keyword '"Wells, Athol U."' showing total 1,816 results
Start Over Author "Wells, Athol U."
1,816 results on '"Wells, Athol U."'

1. Overview of Lung Involvement

Author

Wells, Athol U., Allanore, Yannick, editor, Varga, John, editor, Denton, Christopher P., editor, Kuwana, Masataka, editor, Chung, Lorinda, editor, and Shah, Ami A., editor

Published
2024
Full Text
View/download PDF

3. Cluster analysis of blood biomarkers to identify molecular patterns in pulmonary fibrosis: assessment of a multicentre, prospective, observational cohort with independent validation

Author

Fainberg, Hernan P, Moodley, Yuben, Triguero, Isaac, Corte, Tamera J, Sand, Jannie M B, Leeming, Diana J, Karsdal, Morten A, Wells, Athol U, Renzoni, Elisabetta, Mackintosh, John, Tan, Dino B A, Li, Roger, Porte, Joanne, Braybrooke, Rebecca, Saini, Gauri, Johnson, Simon R, Wain, Louise V, Molyneaux, Philip L, Maher, Toby M, Stewart, Iain D, and Jenkins, R Gisli

Published
2024
Full Text
View/download PDF

5. High-resolution CT phenotypes in pulmonary sarcoidosis: a multinational Delphi consensus study

Author

Anderson, Adam, Morgenthau, Adam, Gaser, Adrian, Vizel, Alexander, Speranskaya, Alexandra, Gerke, Alicia, Goksel, Altinisik, Undurraga, Alvaro, Sharma, Amita, Oh, Andrea, Leung, Ann, Larici, Anna Rita, Prasse, Antje, Mazzei, Antonietta, Morais, Antonio, Bhalla, Ashu, Del Rio, Belen, Jankharia, Bhavin, Elicker, Brett, Pereira, Carlos, Biegelman-Aubry, Catherine, White, Charles, Ravaglia, Claudia, Hsia, Connie, Schaefer-Prokop, Cornelia, Launay, David, Talwar, Deepak, Castillo, Diego, Patel, Divya, Israel-Biet, Dominique, Valeyre, Dominique, Britt, Edward James, Bargagli, Elena, Bendstrup, Elisabeth, Crouser, Elliott, Nossent, Esther, Shmelev, Eugeny, Porquera, Eva Carmona, Bonella, Francesco, Cohen-Aubart, Fleur, Jeny, Florence, Ferrara, Giovanni, Jin, Gong Yong, Robbie, Hasti, Prosch, Helmut, Sumikawa, Hiromitsu, Ling-Pei, Ho, Lee, Ho Yun, Strambu, Irina, Buendia-Roldan, Ivette, Grutters, Jan, Ryu, Jay, Swigris, Jeff, Miedema, Jelle, Goo, Jin Mo, Barnett, Joseph, Verschakelen, Johny, Goldin, Jonathan, Seo, Joon Beom, Enghelmayer, Juan, Mana, Juan, Behr, Juergen, Patterson, Karen, Antoniou, Katerina, Brown, Kevin, Fujimoto, Kiminori, Savale, Laurent, Maier, Lisa, Richeldi, Luca, Neto, Manuel Lessa Ribeiro, Humbert, Marc, Judson, Marc, Veltkamp, Marcel, Wilsher, Margaret, Molina, Maria, Otaola, Maria, Revel, Marie-Pierre, Silva, Mario, Drent, Marjolein, Schiebler, Mark, Wijsenbeek-Lourens, Marlies, Bonifazi, Martina, Remy-Jardin, Martine, Koslow, Matthew, Balter, Meyer, Kreuter, Michael, Thillai, Muhunthan, Hamzeh, Nabeel, Chaudhuri, Nazia, Mogulkoc, Nesrin, Todd, Nevins, Screaton, Nick, Goh, Nicole, Shah, Nirav, Obi, Ogugua, Shlobin, Oksana, Baranova, Olga, Bresser, Paul, Rottoli, Paula, Brillet, Pierre-Yves, Said-Hartley, Qonita, Borie, Raphael, Mostard, Remy, van Zyl-smit, Richard, Kairalla, Ronaldo, Egashira, Ryoko, Boussouar, Samia, Lee, Sang Min, Bhalla, Sanjeev, Tomassetti, Sara, Quadrelli, Silvia, Hart, Simon P, Danoff, Sonye, Rajan, Sujeet, Choi, Sun Mi, Copley, Susan, Kim, Tae Jung, Johkoh, Takeshi, Corte, Tamera, McLoud, Theresa, Wessendorf, Thomas, Alfaro, Tiago, Arai, Toru, Costabel, Ulrich, Vicens-Zygmunt, Vanesa, Poletti, Venerino, Cottin, Vincent, Vucinic, Violeta, Wuyts, Wim, van Es, Wouter, Jeong, Yeon Joo, Inoue, Yoshikazu, Desai, Sujal R, Sivarasan, Nishanth, Johannson, Kerri A, George, Peter M, Culver, Daniel A, Devaraj, Anand, Lynch, David A, Milne, David, Renzoni, Elisabetta, Nunes, Hilario, Sverzellati, Nicola, Spagnolo, Paolo, Baughman, Robert P, Yadav, Ruchi, Piciucchi, Sara, Walsh, Simon L F, Kouranos, Vasileios, and Wells, Athol U

Published
2024
Full Text
View/download PDF

6. Detection and Early Referral of Patients With Interstitial Lung Abnormalities An Expert Survey Initiative

Author

Hunninghake, Gary M, Goldin, Jonathan G, Kadoch, Michael A, Kropski, Jonathan A, Rosas, Ivan O, Wells, Athol U, Yadav, Ruchi, Lazarus, Howard M, Abtin, Fereidoun G, Corte, Tamera J, de Andrade, Joao A, Johannson, Kerri A, Kolb, Martin R, Lynch, David A, Oldham, Justin M, Spagnolo, Paolo, Strek, Mary E, Tomassetti, Sara, Washko, George R, White, Eric S, Group, ILA Study, Abtin, Fereidoun, Antoniou, Katerina, Blackwell, Timothy, Brown, Kevin, Chung, Jonathan, Corte, Tamera, Crestani, Bruno, Crossno, Peter, Culver, Daniel, de Andrade, Joao, Deveraj, Anand, Flaherty, Kevin, Gudmundsson, Gunnar, Hatabu, Hiroto, Jacob, Joe, Johansson, Kerri, Kanne, Jeff, Kazerooni, Ella, Kolb, Martin, Lynch, David, Maher, Toby, Martinez, Fernando, Morais, Antonio, Nathan, Steven D, Noth, Imre, Oldham, Justin, Podolanczuk, Anna, Poletti, Venerino, Ravaglia, Claudia, Renzoni, Elizabetta, Richeldi, Luca, Rubin, Geoffrey, Ryerson, Chris, Sahoo, Debasis, Suh, Rob, Sverzellati, Nicola, Valeyre, Dominique, Walsh, Simon, and Washko, George

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Prevention, Biomedical Imaging, Lung, Clinical Research, 4.4 Population screening, Detection, screening and diagnosis, Respiratory, Disease Progression, Early Diagnosis, Female, Humans, Lung Diseases, Interstitial, Male, Pulmonologists, Radiologists, Referral and Consultation, Respiratory Function Tests, Surveys and Questionnaires, Tomography, X-Ray Computed, CT, fi brosis, interstitial lung abnormalities, interstitial lung disease, survey, ILA Study Group, fibrosis, Respiratory System, Cardiovascular medicine and haematology, Clinical sciences
Abstract

BackgroundInterstitial lung abnormalities (ILA) may represent undiagnosed early-stage or subclinical interstitial lung disease (ILD). ILA are often observed incidentally in patients who subsequently develop clinically overt ILD. There is limited information on consensus definitions for, and the appropriate evaluation of, ILA. Early recognition of patients with ILD remains challenging, yet critically important. Expert consensus could inform early recognition and referral.Research questionCan consensus-based expert recommendations be identified to guide clinicians in the recognition, referral, and follow-up of patients with or at risk of developing early ILDs?Study design and methodsPulmonologists and radiologists with expertise in ILD participated in two iterative rounds of surveys. The surveys aimed to establish consensus regarding ILA reporting, identification of patients with ILA, and identification of populations that might benefit from screening for ILD. Recommended referral criteria and follow-up processes were also addressed. Threshold for consensus was defined a priori as ≥ 75% agreement or disagreement.ResultsFifty-five experts were invited and 44 participated; consensus was reached on 39 of 85 questions. The following clinically important statements achieved consensus: honeycombing and traction bronchiectasis or bronchiolectasis indicate potentially progressive ILD; honeycombing detected during lung cancer screening should be reported as potentially significant (eg, with the Lung CT Screening Reporting and Data System "S-modifier" [Lung-RADS; which indicates clinically significant or potentially significant noncancer findings]), recommending referral to a pulmonologist in the radiology report; high-resolution CT imaging and full pulmonary function tests should be ordered if nondependent subpleural reticulation, traction bronchiectasis, honeycombing, centrilobular ground-glass nodules, or patchy ground-glass opacity are observed on CT imaging; patients with honeycombing or traction bronchiectasis should be referred to a pulmonologist irrespective of diffusion capacity values; and patients with systemic sclerosis should be screened with pulmonary function tests for early-stage ILD.InterpretationGuidance was established for identifying clinically relevant ILA, subsequent referral, and follow-up. These results lay the foundation for developing practical guidance on managing patients with ILA.

Published
2022

7. Systemic Sclerosis and the Lung

Author

Wells, Athol U., Margaritopoulos, George A., Antoniou, Katerina M., Nicholson, Andrew G., Cottin, Vincent, editor, Richeldi, Luca, editor, Brown, Kevin, editor, and McCormack, Francis X., editor

Published
2023
Full Text
View/download PDF

10. The Role of Chest Imaging in Patient Management During the COVID-19 Pandemic A Multinational Consensus Statement From the Fleischner Society

Author

Rubin, Geoffrey D, Ryerson, Christopher J, Haramati, Linda B, Sverzellati, Nicola, Kanne, Jeffrey P, Raoof, Suhail, Schluger, Neil W, Volpi, Annalisa, Yim, Jae-Joon, Martin, Ian BK, Anderson, Deverick J, Kong, Christina, Altes, Talissa, Bush, Andrew, Desai, Sujal R, Goldin, Jonathan, Goo, Jin Mo, Humbert, Marc, Inoue, Yoshikazu, Kauczor, Hans-Ulrich, Luo, Fengming, Mazzone, Peter J, Prokop, Mathias, Remy-Jardin, Martine, Richeldi, Luca, Schaefer-Prokop, Cornelia M, Tomiyama, Noriyuki, Wells, Athol U, and Leung, Ann N

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Patient Safety, Lung, Prevention, Infection, Good Health and Well Being, Betacoronavirus, COVID-19, Coronavirus Infections, Diagnosis, Differential, Disease Progression, Early Diagnosis, Humans, International Cooperation, Pandemics, Patient Care Management, Pneumonia, Viral, Radiography, Thoracic, Respiratory Tract Diseases, SARS-CoV-2, Tomography, X-Ray Computed, Respiratory System, Cardiovascular medicine and haematology, Clinical sciences
Abstract

With more than 900,000 confirmed cases worldwide and nearly 50,000 deaths during the first 3 months of 2020, the coronavirus disease 2019 (COVID-19) pandemic has emerged as an unprecedented health care crisis. The spread of COVID-19 has been heterogeneous, resulting in some regions having sporadic transmission and relatively few hospitalized patients with COVID-19 and others having community transmission that has led to overwhelming numbers of severe cases. For these regions, health care delivery has been disrupted and compromised by critical resource constraints in diagnostic testing, hospital beds, ventilators, and health care workers who have fallen ill to the virus exacerbated by shortages of personal protective equipment. Although mild cases mimic common upper respiratory viral infections, respiratory dysfunction becomes the principal source of morbidity and mortality as the disease advances. Thoracic imaging with chest radiography and CT are key tools for pulmonary disease diagnosis and management, but their role in the management of COVID-19 has not been considered within the multivariable context of the severity of respiratory disease, pretest probability, risk factors for disease progression, and critical resource constraints. To address this deficit, a multidisciplinary panel comprised principally of radiologists and pulmonologists from 10 countries with experience managing patients with COVID-19 across a spectrum of health care environments evaluated the utility of imaging within three scenarios representing varying risk factors, community conditions, and resource constraints. Fourteen key questions, corresponding to 11 decision points within the three scenarios and three additional clinical situations, were rated by the panel based on the anticipated value of the information that thoracic imaging would be expected to provide. The results were aggregated, resulting in five main and three additional recommendations intended to guide medical practitioners in the use of chest radiography and CT in the management of COVID-19.

Published
2020

12. Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial

Author

Akil, Mohammed, Babalis, Daphne, Chaudhuri, Nazia, Chua, Felix, Data, Arnab, Desai, Dhananjay, Dubey, Shrish, Dwyer, Natalie, Flather, Marcus, Fordham, Richard, Grossi Sampedro, Carlota, Hall, Frances, Jakupovic, Ira, Keir, Gregory, Patel, Bipen, Penn, Henry, Rajasekaran, Arvind, Spencer, Lisa G, Tsipouri, Vicky, Wu, Zhe, Xydopoulos, Georgio, Zanghelini, Fernando, Maher, Toby M, Tudor, Veronica A, Saunders, Peter, Gibbons, Michael A, Fletcher, Sophie V, Denton, Christopher P, Hoyles, Rachel K, Parfrey, Helen, Renzoni, Elisabetta A, Kokosi, Maria, Wells, Athol U, Ashby, Deborah, Szigeti, Matyas, and Molyneaux, Philip L

Published
2023
Full Text
View/download PDF

13. Genetic burden of dysregulated cytoskeletal organisation in the pathogenesis of pulmonary fibrosis

Author

Wang, Dapeng, primary, Ni, Yujie, additional, Liu, Bin, additional, Ding, Huan, additional, John, Alison, additional, Wain, Louise V, additional, Johnson, Simon R., additional, Maher, Toby M, additional, Molyneaux, Philip L, additional, Renzoni, Elizabeth, additional, Saini, Gauri, additional, Wells, Athol U, additional, Morris-Rosendahl, Deborah, additional, Jenkins, R Gisli, additional, and Stewart, Iain, additional

Published
2024
Full Text
View/download PDF

15. Forced vital capacity trajectories in patients with idiopathic pulmonary fibrosis: a secondary analysis of a multicentre, prospective, observational cohort

Author

Fainberg, Hernan P, Oldham, Justin M, Molyneaux, Philip L, Allen, Richard J, Kraven, Luke M, Fahy, William A, Porte, Joanne, Braybrooke, Rebecca, Saini, Gauri, Karsdal, Morten A, Leeming, Diane J, Sand, Jannie M B, Triguero, Isaac, Oballa, Eunice, Wells, Athol U, Renzoni, Elisabetta, Wain, Louise V, Noth, Imre, Maher, Toby M, Stewart, Iain D, and Jenkins, R Gisli

Published
2022
Full Text
View/download PDF

16. Integration and Application of Clinical Practice Guidelines for the Diagnosis of Idiopathic Pulmonary Fibrosis and Fibrotic Hypersensitivity Pneumonitis

Author

Marinescu, Daniel-Costin, Raghu, Ganesh, Remy-Jardin, Martine, Travis, William D., Adegunsoye, Ayodeji, Beasley, Mary Beth, Chung, Jonathan H., Churg, Andrew, Cottin, Vincent, Egashira, Ryoko, Fernández Pérez, Evans R., Inoue, Yoshikazu, Johannson, Kerri A., Kazerooni, Ella A., Khor, Yet H., Lynch, David A., Müller, Nestor L., Myers, Jeffrey L., Nicholson, Andrew G., Rajan, Sujeet, Saito-Koyama, Ryoko, Troy, Lauren, Walsh, Simon L.F., Wells, Athol U., Wijsenbeek, Marlies S., Wright, Joanne L., and Ryerson, Christopher J.

Published
2022
Full Text
View/download PDF

17. The six-minute walk test in sarcoidosis associated pulmonary hypertension: Results from an international registry

Author

Gupta, Rohit, Baughman, Robert P., Nathan, Steven D., Wells, Athol U., Kouranos, Vasilis, Alhamad, Esam H., Culver, Daniel A., Barney, Joseph, Carmona, Eva M., Cordova, Francis C., Huitema, Marloes, Scholand, Mary Beth, Wijsenbeek, Marlies, Ganesh, Sivagini, Birring, Surinder S., Price, Laura C., Wort, Stephen John, and Shlobin, Oksana A.

Published
2022
Full Text
View/download PDF

18. Detection and Early Referral of Patients With Interstitial Lung Abnormalities: An Expert Survey Initiative

Author

Abtin, Fereidoun, Antoniou, Katerina, Blackwell, Timothy, Brown, Kevin, Chung, Jonathan, Corte, Tamera, Crestani, Bruno, Crossno, Peter, Culver, Daniel, de Andrade, Joao, Deveraj, Anand, Flaherty, Kevin, Gudmundsson, Gunnar, Hatabu, Hiroto, Jacob, Joe, Johansson, Kerri, Kanne, Jeff, Kazerooni, Ella, Kolb, Martin, Lynch, David, Maher, Toby, Martinez, Fernando, Morais, Antonio, Nathan, Steven D., Noth, Imre, Oldham, Justin, Podolanczuk, Anna, Poletti, Venerino, Ravaglia, Claudia, Renzoni, Elizabetta, Richeldi, Luca, Rubin, Geoffrey, Ryerson, Chris, Sahoo, Debasis, Tomassetti, Sara, Spagnolo, Paolo, Strek, Mary E., Suh, Rob, Sverzellati, Nicola, Valeyre, Dominique, Walsh, Simon, Washko, George, White, Eric S., Hunninghake, Gary M., Goldin, Jonathan G., Kadoch, Michael A., Kropski, Jonathan A., Rosas, Ivan O., Wells, Athol U., Yadav, Ruchi, Lazarus, Howard M., Abtin, Fereidoun G., Corte, Tamera J., de Andrade, Joao A., Johannson, Kerri A., Kolb, Martin R., Lynch, David A., Oldham, Justin M., and Washko, George R.

Published
2022
Full Text
View/download PDF

20. The Role of Inflammation and Fibrosis in Interstitial Lung Disease Treatment Decisions.

Author

Behr, Juergen, Salisbury, Margaret L., Walsh, Simon L. F., Podolanczuk, Anna J., Hariri, Lida P., Hunninghake, Gary M., Kolb, Martin, Ryerson, Christopher J., Cottin, Vincent, Beasley, Mary B., Corte, Tamera, Glanville, Allan R., Adegunsoye, Ayodeji, Hogaboam, Cory, Wuyts, Wim A., Noth, Imre, Oldham, Justin M., Richeldi, Luca, Raghu, Ganesh, and Wells, Athol U.

Subjects
PULMONARY fibrosis, INTERSTITIAL lung diseases, THERAPEUTICS, IDIOPATHIC diseases, IDIOPATHIC pulmonary fibrosis, MONONUCLEAR leukocytes
Abstract

The article summarizes knowledge on inflammation and fibrosis in interstitial lung disease (ILD), with the relative burden of each in an individual patient gleaned by considering several domains, including clinical history and lung function, imaging, laboratory including bronchoalveolar lavage (BAL), and histopathology. Topics discussed include prediction of disease behavior and first-line treatment decision, inflammation in ILD, and fibrosis in ILD.

Published
2024
Full Text
View/download PDF

22. The Role of Inflammation and Fibrosis in ILD Treatment Decisions

Author

Behr, Juergen, primary, Salisbury, Margaret L, additional, Walsh, Simon L. F., additional, Podolanczuk, Anna J., additional, Hariri, Lida P, additional, Hunninghake, Gary M, additional, Kolb, Martin, additional, Ryerson, Christopher J, additional, Cottin, Vincent, additional, Beasley, Mary B., additional, Corte, Tamera, additional, Glanville, Allan R, additional, Adegunsoye, Ayodeji, additional, Hogaboam, Cory, additional, Wuyts, Wim A., additional, Noth, Imre, additional, Oldham, Justin M., additional, Richeldi, Luca, additional, Raghu, Ganesh, additional, and Wells, Athol U., additional

Published
2024
Full Text
View/download PDF

23. The impact of hiatus hernia in hypersensitivity pneumonitis

Author

Heriot, David A., primary, Stock, Carmel J. W., additional, Mumtaz, Zain‐Ul‐Abideen, additional, Jenkins, R. Gisli, additional, Chua, Felix, additional, Molyneaux, Phillip L., additional, Devaraj, Anand, additional, Kouranos, Vasilis, additional, Wells, Athol U., additional, Renzoni, Elizabetta A., additional, Padley, Simon P. G., additional, Desai, Sujal R., additional, and George, Peter M., additional

Published
2024
Full Text
View/download PDF

24. Rituximab compared to intravenous cyclophosphamide in adults with connective tissue disease-associated interstitial lung disease: the RECITAL RCT

Author

Maher, Toby M, primary, Tudor, Veronica A, additional, Saunders, Peter, additional, Zanghelini, Fernando, additional, Grossi Sampedro, Carlota, additional, Xydopoulos, Georgios, additional, Gibbons, Michael, additional, Fletcher, Sophie V, additional, Denton, Christopher P, additional, Kokosi, Maria, additional, Hoyles, Rachel K, additional, Parfrey, Helen, additional, Renzoni, Elisabetta A, additional, Wells, Athol U, additional, Ashby, Deborah, additional, Fordham, Richard J, additional, Szigeti, Matyas, additional, and Molyneaux, Philip L, additional

Published
2024
Full Text
View/download PDF

29. Real-world experience of nintedanib for progressive fibrosing interstitial lung disease in the UK

Author

Dixon, Giles, primary, Hague, Samuel, additional, Mulholland, Sarah, additional, Adamali, Huzaifa, additional, Khin, Aye Myat Noe, additional, Thould, Hannah, additional, Connon, Roisin, additional, Minnis, Paul, additional, Murtagh, Eoin, additional, Khan, Fasihul, additional, Toor, Sameen, additional, Lawrence, Alexandra, additional, Naqvi, Marium, additional, West, Alex, additional, Coker, Robina K., additional, Ward, Katie, additional, Yazbeck, Leda, additional, Hart, Simon, additional, Garfoot, Theresa, additional, Newman, Kate, additional, Rivera-Ortega, Pilar, additional, Stranks, Lachlan, additional, Beirne, Paul, additional, Bradley, Jessica, additional, Rowan, Catherine, additional, Agnew, Sarah, additional, Ahmad, Mahin, additional, Spencer, Lisa G., additional, Aigbirior, Joshua, additional, Fahim, Ahmed, additional, Wilson, Andrew M., additional, Butcher, Elizabeth, additional, Chong, Sy Giin, additional, Saini, Gauri, additional, Zulfikar, Sabrina, additional, Chua, Felix, additional, George, Peter M., additional, Kokosi, Maria, additional, Kouranos, Vasileios, additional, Molyneaux, Philip, additional, Renzoni, Elisabetta, additional, Vitri, Benedetta, additional, Wells, Athol U., additional, Nicol, Lisa M., additional, Bianchi, Stephen, additional, Kular, Raman, additional, Liu, HuaJian, additional, John, Alexander, additional, Barth, Sarah, additional, Wickremasinghe, Melissa, additional, Forrest, Ian A., additional, Grimes, Ian, additional, Simpson, A. John, additional, Fletcher, Sophie V., additional, Jones, Mark G., additional, Kinsella, Emma, additional, Naftel, Jennifer, additional, Wood, Nicola, additional, Chalmers, Jodie, additional, Crawshaw, Anjali, additional, Crowley, Louise E., additional, Dosanjh, Davinder, additional, Huntley, Christopher C., additional, Walters, Gareth I., additional, Gatheral, Timothy, additional, Plum, Catherine, additional, Bikmalla, Shiva, additional, Muthusami, Raja, additional, Stone, Helen, additional, Rodrigues, Jonathan C.L., additional, Tsaneva-Atanasova, Krasimira, additional, Scotton, Chris J., additional, Gibbons, Michael A., additional, and Barratt, Shaney L., additional

Published
2024
Full Text
View/download PDF

31. Pleuroparenchymal fibroelastosis in idiopathic pulmonary fibrosis: Survival analysis using visual and computer-based computed tomography assessment

Author

Gudmundsson, Eyjolfur, Zhao, An, Mogulkoc, Nesrin, Stewart, Iain, Jones, Mark G., Van Moorsel, Coline H.M., Savas, Recep, Brereton, Christopher J., Van Es, Hendrik W., Unat, Omer, Pontoppidan, Katarina, Van Beek, Frouke, Veltkamp, Marcel, Gholipour, Bahareh, Nair, Arjun, Wells, Athol U., Janes, Sam M., Alexander, Daniel C., and Jacob, Joseph

Published
2021
Full Text
View/download PDF

33. Efficacy and safety of sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: a double-blind, randomised, placebo-controlled, phase 2b trial

Author

Behr, Jürgen, Nathan, Steven D, Wuyts, Wim A, Mogulkoc Bishop, Nesrin, Bouros, Demosthenes E, Antoniou, Katerina, Guiot, Julien, Kramer, Mordechai R, Kirchgaessler, Klaus-Uwe, Bengus, Monica, Gilberg, Frank, Perjesi, Andras, Harari, Sergio, and Wells, Athol U

Published
2021
Full Text
View/download PDF

34. Design of the PF-ILD trial: a double-blind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung disease

Author

Flaherty, Kevin R, Brown, Kevin K, Wells, Athol U, Clerisme-Beaty, Emmanuelle, Collard, Harold R, Cottin, Vincent, Devaraj, Anand, Inoue, Yoshikazu, Le Maulf, Florence, Richeldi, Luca, Schmidt, Hendrik, Walsh, Simon, Mezzanotte, William, and Schlenker-Herceg, Rozsa

Subjects
Lung, Autoimmune Disease, Clinical Trials and Supportive Activities, Clinical Research, Rare Diseases, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Respiratory, Good Health and Well Being, interstitial fibrosis, rare lung diseases
Abstract

600 patients aged ≥18 years will be randomised in a 1:1 ratio to nintedanib or placebo. Patients with diagnosis of IPF will be excluded. The study population will be enriched with two-thirds having a usual interstitial pneumonia-like pattern on HRCT. The primary endpoint is the annual rate of decline in forced vital capacity over 52 weeks. The main secondary endpoints are the absolute change from baseline in King's Brief Interstitial Lung Disease Questionnaire total score, time to first acute interstitial lung disease exacerbation or death and time to all-cause mortality over 52 weeks.Ethics and disseminationThe trial is conducted in accordance with the Declaration of Helsinki, the International Conference on Harmonisation Tripartite Guideline for Good Clinical Practice (GCP) and Japanese GCP regulations.Trial registration numberNCT02999178.

Published
2017

37. Low bleeding rates following transbronchial lung cryobiopsy in unclassifiable interstitial lung disease.

Author

Taverner, John, Lucena, Carmen M., Garner, Justin L., Orton, Christopher M., Nicholson, Andrew G., Desai, Sujal R., Wells, Athol U., and Shah, Pallav L.

Subjects
CRYOSURGERY, BRONCHIECTASIS, INTERSTITIAL lung diseases, ORTHOPEDIC traction, RED blood cell transfusion, BRONCHIAL arteries, LUNGS, HEMORRHAGE
Abstract

Background and Objective: Bronchoscopic transbronchial lung cryobiopsy (TBLC) is a guideline‐endorsed alternative to surgical lung biopsy for tissue diagnosis in unclassifiable interstitial lung disease (ILD). The reported incidence of post‐procedural bleeding has varied widely. We aimed to characterize the incidence, severity and risk factors for clinically significant bleeding following TBLC using an expert‐consensus airway bleeding scale, in addition to other complications and diagnostic yield. Methods: A retrospective cohort study of consecutive adult outpatients with unclassifiable ILD who underwent TBLC following multidisciplinary discussion at a single centre in the UK between July 2016 and December 2021. TBLC was performed under general anaesthesia with fluoroscopic guidance and a prophylactic endobronchial balloon. Results: One hundred twenty‐six patients underwent TBLC (68.3% male; mean age 62.7 years; FVC 86.2%; DLCO 54.5%). Significant bleeding requiring balloon blocker reinflation for >20 min, admission to ICU, packed red blood cell transfusion, bronchial artery embolization, resuscitation or procedural abandonment, occurred in 10 cases (7.9%). Significant bleeding was associated with traction bronchiectasis on HRCT (OR 7.1, CI 1.1–59.1, p = 0.042), a TBLC histological pattern of UIP (OR 4.0, CI 1.1–14, p = 0.046) and the presence of medium‐large vessels on histology (OR 37.3, CI 6.5–212, p < 0.001). BMI ≥30 (p = 0.017) and traction bronchiectasis on HRCT (p = 0.025) were significant multivariate predictors of longer total bleeding time (p = 0.017). Pneumothorax occurred in nine cases (7.1%) and the 30‐day mortality was 0%. Diagnostic yield was 80.6%. Conclusion: TBLC has an acceptable safety profile in experienced hands. Radiological traction bronchiectasis and obesity increase the risk of significant bleeding following TBLC. Transbronchial lung cryobiopsy can be performed safely in experienced hands. Radiological traction bronchiectasis and obesity increase the risk of significant bleeding. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

38. High-resolution CT phenotypes in pulmonary sarcoidosis: a multinational Delphi consensus study.

Author

Desai, Sujal R, Sivarasan, Nishanth, Johannson, Kerri A, George, Peter M, Culver, Daniel A, Devaraj, Anand, Lynch, David A, Milne, David, Renzoni, Elisabetta, Nunes, Hilario, Sverzellati, Nicola, Spagnolo, Paolo, Baughman, Robert P, Yadav, Ruchi, Piciucchi, Sara, Walsh, Simon L F, Kouranos, Vasileios, and Wells, Athol U

Subjects
DELPHI method, SARCOIDOSIS, PHENOTYPES, LIKERT scale, PHYSICIANS
Abstract

One view of sarcoidosis is that the term covers many different diseases. However, no classification framework exists for the future exploration of pathogenetic pathways, genetic or trigger predilections, patterns of lung function impairment, or treatment separations, or for the development of diagnostic algorithms or relevant outcome measures. We aimed to establish agreement on high-resolution CT (HRCT) phenotypic separations in sarcoidosis to anchor future CT research through a multinational two-round Delphi consensus process. Delphi participants included members of the Fleischner Society and the World Association of Sarcoidosis and other Granulomatous Disorders, as well as members' nominees. 146 individuals (98 chest physicians, 48 thoracic radiologists) from 28 countries took part, 144 of whom completed both Delphi rounds. After rating of 35 Delphi statements on a five-point Likert scale, consensus was achieved for 22 (63%) statements. There was 97% agreement on the existence of distinct HRCT phenotypes, with seven HRCT phenotypes that were categorised by participants as non-fibrotic or likely to be fibrotic. The international consensus reached in this Delphi exercise justifies the formulation of a CT classification as a basis for the possible definition of separate diseases. Further refinement of phenotypes with rapidly achievable CT studies is now needed to underpin the development of a formal classification of sarcoidosis. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

40. Prognostic value of transbronchial lung cryobiopsy for the multidisciplinary diagnosis of idiopathic pulmonary fibrosis: a retrospective validation study

Author

Tomassetti, Sara, Ravaglia, Claudia, Wells, Athol U, Cavazza, Alberto, Colby, Thomas V, Rossi, Giulio, Ley, Brett, Ryu, Jay H, Puglisi, Silvia, Arcadu, Antonella, Marchi, Martina, Sultani, Fabio, Martinello, Sabrina, Donati, Luca, Gurioli, Carlo, Gurioli, Christian, Tantalocco, Paola, Hetzel, Jurgen, Dubini, Alessandra, Piciucchi, Sara, Klersy, Catherine, Lavorini, Federico, and Poletti, Venerino

Published
2020
Full Text
View/download PDF

41. Interstitial lung abnormalities detected incidentally on CT: a Position Paper from the Fleischner Society

Author

Hatabu, Hiroto, Hunninghake, Gary M, Richeldi, Luca, Brown, Kevin K, Wells, Athol U, Remy-Jardin, Martine, Verschakelen, Johny, Nicholson, Andrew G, Beasley, Mary B, Christiani, David C, San José Estépar, Raúl, Seo, Joon Beom, Johkoh, Takeshi, Sverzellati, Nicola, Ryerson, Christopher J, Graham Barr, R, Goo, Jin Mo, Austin, John H M, Powell, Charles A, Lee, Kyung Soo, Inoue, Yoshikazu, and Lynch, David A

Published
2020
Full Text
View/download PDF

42. Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial

Author

Abe, S., Aburto, M., Acosta, O., Andrews, C., Antin-Ozerkis, D., Arce, G., Arias, M., Avdeev, S., Barczyk, A., Bascom, R., Bazdyrev, E., Beirne, P., Belloli, E., Bergna, M.A., Bergot, E., Bhatt, N., Blaas, S., Bondue, B., Bonella, F., Britt, E., Buch, K., Burk, J., Cai, H., Cantin, A., Castillo Villegas, D.M., Cazaux, A., Cerri, S., Chaaban, S., Chaudhuri, N., Cottin, V., Crestani, B., Criner, G., Dahlqvist, C., Danoff, S., Dematte D'Amico, J., Dilling, D., Elias, P., Ettinger, N., Falk, J., Fernández Pérez, E.R., Gamez-Dubuis, A., Giessel, G., Gifford, A., Glassberg, M., Glazer, C., Golden, J., Gómez Carrera, L., Guiot, J., Hallowell, R., Hayashi, H., Hetzel, J., Hirani, N., Homik, L., Hope-Gill, B., Hotchkin, D., Ichikado, K., Ilkovich, M., Inoue, Y., Izumi, S., Jassem, E., Jones, L., Jouneau, S., Kaner, R., Kang, J., Kawamura, T., Kessler, R., Kim, Y., Kishi, K., Kitamura, H., Kolb, M., Kondoh, Y., Kono, C., Koschel, D., Kreuter, M., Kulkarni, T., Kus, J., Lebargy, F., León Jiménez, A., Luo, Q., Mageto, Y., Maher, T.M., Makino, S., Marchand-Adam, S., Marquette, C., Martinez, R., Martínez, M., Maturana Rozas, R., Miyazaki, Y., Moiseev, S., Molina-Molina, M., Morrison, L., Morrow, L., Moua, T., Nambiar, A., Nishioka, Y., Nunes, H., Okamoto, M., Oldham, J., Otaola, M., Padilla, M., Park, J.S., Patel, N., Pesci, A., Piotrowski, W., Pitts, L., Poonyagariyagorn, H., Prasse, A., Quadrelli, S., Randerath, W., Refini, R., Reynaud-Gaubert, M., Riviere, F., Rodríguez Portal, J.A., Rosas, I., Rossman, M., Safdar, Z., Saito, T., Sakamoto, N., Salinas Fénero, M., Sauleda, J., Schmidt, S., Scholand, M.B., Schwartz, M., Shapera, S., Shlobin, O., Sigal, B., Silva Orellana, A., Skowasch, D., Song, J.W., Stieglitz, S., Stone, H., Strek, M., Suda, T., Sugiura, H., Takahashi, H., Takaya, H., Takeuchi, T., Thavarajah, K., Tolle, L., Tomassetti, S., Tomii, K., Valenzuela, C., Vancheri, C., Varone, F., Veeraraghavan, S., Villar, A., Weigt, S., Wemeau, L., Wuyts, W., Xu, Z., Yakusevich, V., Yamada, Y., Yamauchi, H., Ziora, D., Wells, Athol U, Flaherty, Kevin R, Brown, Kevin K, Inoue, Yoshikazu, Devaraj, Anand, Richeldi, Luca, Moua, Teng, Crestani, Bruno, Wuyts, Wim A, Stowasser, Susanne, Quaresma, Manuel, Goeldner, Rainer-Georg, Schlenker-Herceg, Rozsa, and Kolb, Martin

Published
2020
Full Text
View/download PDF

44. The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis

Author

Khanna, Dinesh, Berrocal, Veronica J, Giannini, Edward H, Seibold, James R, Merkel, Peter A, Mayes, Maureen D, Baron, Murray, Clements, Philip J, Steen, Virginia, Assassi, Shervin, Schiopu, Elena, Phillips, Kristine, Simms, Robert W, Allanore, Yannick, Denton, Christopher P, Distler, Oliver, Johnson, Sindhu R, Matucci-Cerinic, Marco, Pope, Janet E, Proudman, Susanna M, Siegel, Jeffrey, Wong, Weng Kee, Wells, Athol U, and Furst, Daniel E

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Clinical Research, Scleroderma, Inflammatory and immune system, Adult, Female, Humans, Male, Middle Aged, Psychometrics, Randomized Controlled Trials as Topic, Rheumatology, Scleroderma, Diffuse, Severity of Illness Index, Public Health and Health Services, Psychology, Clinical sciences, Allied health and rehabilitation science
Abstract

ObjectiveEarly diffuse cutaneous systemic sclerosis (dcSSc) is characterized by rapid changes in the skin and internal organs. The objective of this study was to develop a composite response index in dcSSc (CRISS) for use in randomized controlled trials (RCTs).MethodsWe developed 150 paper patient profiles with standardized clinical outcome elements (core set items) using patients with dcSSc. Forty scleroderma experts rated 20 patient profiles each and assessed whether each patient had improved or not improved over a period of 1 year. Using the profiles for which raters had reached a consensus on whether the patients were improved versus not improved (79% of the profiles examined), we fit logistic regression models in which the binary outcome referred to whether the patient was improved or not, and the changes in the core set items from baseline to followup were entered as covariates. We tested the final index in a previously completed RCT.ResultsSixteen of 31 core items were included in the patient profiles after a consensus meeting and review of test characteristics of patient-level data. In the logistic regression model in which the included core set items were change over 1 year in the modified Rodnan skin thickness score, the forced vital capacity, the patient and physician global assessments, and the Health Assessment Questionnaire disability index, sensitivity was 0.982 (95% confidence interval 0.982-0.983) and specificity was 0.931 (95% confidence interval 0.930-0.932), and the model with these 5 items had the highest face validity. Subjects with a significant worsening of renal or cardiopulmonary involvement were classified as not improved, regardless of improvements in other core items. With use of the index, the effect of methotrexate could be differentiated from the effect of placebo in a 1-year RCT (P = 0.02).ConclusionWe have developed a CRISS that is appropriate for use as an outcome assessment in RCTs of early dcSSc.

Published
2016

45. Overnight desaturation in interstitial lung diseases: links to pulmonary vasculopathy and mortality

Author

Margaritopoulos, George A., primary, Proklou, Athanasia, additional, Trachalaki, Athina, additional, Badenes Bonet, Diana, additional, Kokosi, Maria, additional, Kouranos, Vasilis, additional, Chua, Felix, additional, George, Peter, additional, Renzoni, Elisabetta A., additional, Devaraj, Anand, additional, Desai, Sujal, additional, Nicholson, Andrew G., additional, Antoniou, Katerina M., additional, and Wells, Athol U., additional

Published
2023
Full Text
View/download PDF

46. Approach to Clinical Trials for the Prevention of Pulmonary Fibrosis

Author

Kim, John S., primary, Montesi, Sydney B., additional, Adegunsoye, Ayodeji, additional, Humphries, Stephen M., additional, Salisbury, Margaret L., additional, Hariri, Lida P., additional, Kropski, Jonathan A., additional, Richeldi, Luca, additional, Wells, Athol U., additional, Walsh, Simon, additional, Jenkins, R. Gisli, additional, Rosas, Ivan, additional, Noth, Imre, additional, Hunninghake, Gary M., additional, Martinez, Fernando J., additional, and Podolanczuk, Anna J., additional

Published
2023
Full Text
View/download PDF

47. Mortality surrogates in combined pulmonary fibrosis and emphysema

Author

Zhao, An, primary, Gudmundsson, Eyjolfur, additional, Mogulkoc, Nesrin, additional, van Moorsel, Coline, additional, Corte, Tamera J., additional, Vasudev, Pardeep, additional, Romei, Chiara, additional, Chapman, Robert, additional, Wallis, Tim J.M., additional, Denneny, Emma, additional, Goos, Tinne, additional, Savas, Recep, additional, Ahmed, Asia, additional, Brereton, Christopher J., additional, van Es, Hendrik W., additional, Jo, Helen, additional, De Liperi, Annalisa, additional, Duncan, Mark, additional, Pontoppidan, Katarina, additional, De Sadeleer, Laurens J., additional, van Beek, Frouke, additional, Barnett, Joseph, additional, Cross, Gary, additional, Procter, Alex, additional, Veltkamp, Marcel, additional, Hopkins, Peter, additional, Moodley, Yuben, additional, Taliani, Alessandro, additional, Taylor, Magali, additional, Verleden, Stijn, additional, Tavanti, Laura, additional, Vermant, Marie, additional, Nair, Arjun, additional, Stewart, Iain, additional, Janes, Sam M., additional, Young, Alexandra L., additional, Barber, David, additional, Alexander, Daniel C., additional, Porter, Joanna C., additional, Wells, Athol U., additional, Jones, Mark G., additional, Wuyts, Wim A., additional, and Jacob, Joseph, additional

Published
2023
Full Text
View/download PDF

48. Pulmonary hemodynamics and transplant‐free survival in sarcoidosis‐associated pulmonary hypertension: Results from an international registry

Author

Gayen, Shameek K., primary, Baughman, Robert P., additional, Nathan, Steven D., additional, Wells, Athol U., additional, Kouranos, Vasilis, additional, Alhamad, Esam H., additional, Culver, Daniel A., additional, Barney, Joseph, additional, Carmoma, Eva M., additional, Cordova, Francis C., additional, Huitema, Marloes, additional, Scholand, Mary Beth, additional, Wijsenbeek, Marlies, additional, Ganesh, Sivagini, additional, Birring, Surinder S., additional, Price, Laura C., additional, Wort, Stephen J., additional, Shlobin, Oksana A., additional, and Gupta, Rohit, additional

Published
2023
Full Text
View/download PDF

50. Defining genetic risk factors for scleroderma-associated interstitial lung disease: IRF5 and STAT4 gene variants are associated with scleroderma while STAT4 is protective against scleroderma-associated interstitial lung disease

Author

Stock, Carmel J. W., De Lauretis, Angelo, Visca, Dina, Daccord, Cecile, Kokosi, Maria, Kouranos, Vasilis, Margaritopoulos, George, George, Peter M., Molyneaux, Philip L., Nihtyanova, Svetlana, Chua, Felix, Maher, Toby M., Ong, Voon, Abraham, David J., Denton, Christopher P., Wells, Athol U., Wain, Louise V., and Renzoni, Elisabetta A.

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results